phrykt

Immucell Corp /De/ (ICCC): who owns it and who trades it

As of Nov 16, 2026, ICCC insiders reported 8 purchases worth $172K in the last 12 months. The largest buyer was Boekhorst Paul Francis Olivier te (CEO), with $156K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Immucell

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ICCC

30 funds and institutions reported ICCC shares worth $13M at the end of Q2 2026, about 14% of the company. The largest holder is Vanguard Capital Management LLC with 3.0%.

Funds and institutions (13F) 14%Everyone else 86%

10 largest owners, by share of the company

Vanguard Capital Management LLC3.0%
Morgan Stanley2.6%
Renaissance Technologies LLC1.9%
Cresset Asset Management, LLC1.5%
Geode Capital Management, LLC0.8%
Dimensional Fund Advisors LP0.6%
Bleichroeder LP0.6%
Steadtrust LLC0.5%
Mesirow Financial Investment Management, Inc.0.5%
Citadel Advisors LLC0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC268,1302.96%$2.7M–
Morgan Stanley233,9102.59%$2.4M–
Renaissance Technologies LLC171,0891.89%$1.7M–
Cresset Asset Management, LLC135,2671.50%$1.4M–
Geode Capital Management, LLC72,2700.80%$726K–
Dimensional Fund Advisors LP58,4520.65%$587K–
Bleichroeder LP50,0000.55%$502K–
Steadtrust LLC45,3700.50%$456K–
Mesirow Financial Investment Management, Inc.42,4810.47%$427K–
Citadel Advisors LLC40,5030.45%$407K–
Vanguard Fiduciary Trust Co37,7660.42%$380K–
HighTower Advisors, LLC24,3540.27%$245K–
BlackRock, Inc.22,8600.25%$230K–
Jane Street Group, LLC15,7510.17%$158K–
Quadrature Capital Ltd15,4150.17%$155K–
Northern Trust Corp14,7210.16%$148K–
Mercer Global Advisors Inc12,0000.13%$121K–
Bailard, Inc.10,1020.11%$102K–
Militia Capital Management LLC10,0000.11%$100K–
Shufro Rose & Co LLC10,0000.11%$100K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ICCC insiders reported $172K of open-market purchases and $0 of sales.

Purchases, 12 months
$172K
8 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 18, 2026
Filed Jun 22, 2026

Purchases and sales by month

$80.1K$80.1KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 18, 2026Boekhorst Paul Francis Olivier teCEOPurchase8,000$9.50$76KForm 4
Dec 4, 2025Boekhorst Paul Francis Olivier teCEOPurchase2,432$5.50$13.4KForm 4
Dec 3, 2025Boekhorst Paul Francis Olivier teCEOPurchase3,598$5.05$18.2KForm 4
Dec 3, 2025Boekhorst Paul Francis Olivier teCEOPurchase2,556$5.00$12.8KForm 4
Dec 3, 2025Boekhorst Paul Francis Olivier teCEOPurchase3,521$5.04$17.7KForm 4
Dec 2, 2025Boekhorst Paul Francis Olivier teCEOPurchase3,708$4.87$18.1KForm 4
Nov 25, 2025David Scott TomscheDirectorPurchase1,633$4.76$7.8KForm 4
Nov 25, 2025David Scott TomscheDirectorPurchase1,633$4.77$7.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Boekhorst Paul Francis Olivier tePresident and CEO, Director$156K–Jun 18, 2026
David Scott TomscheDirector$15.6K–Nov 25, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ICCC short interest

Low short interest. 0.2% of ICCC shares are sold short: about 1 share in 618. Over the last 12 reports the number of shares short went up 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14,706 ICCC shares were sold short, 0.2% of the shares outstanding, down 18.8% from the report before. At the average daily volume of 5,271 shares, buying them all back would take about 2.8 trading days (days to cover).

Shares short, % of all shares

0.16%May 15Oct 300.26%

Days to cover

2.8May 15Oct 303.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614,7060.16%-19%5,2712.8
Oct 15, 202618,1030.20%-18%13,3851.4
Sep 30, 202622,1120.24%+12%12,5421.8
Sep 15, 202619,8280.22%+3%12,7141.6
Aug 31, 202619,2690.21%+27%34,2101.0
Aug 14, 202615,2240.17%-14%29,7151.0
Jul 31, 202617,6050.19%+25%19,0091.0
Jul 15, 202614,0480.16%-25%41,6641.0
Jun 30, 202618,7160.21%+52%32,8061.0
Jun 15, 202612,2810.14%+35%17,6681.0
May 29, 20269,0880.10%-13%44,2271.0
May 15, 202610,4350.12%-43%27,3031.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Immucell company events

Immucell filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 13, 2026.

  1. Oct 13, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Jul 9, 2026ResultsReleased financial results. Filing
  4. Jun 17, 2026VoteReported shareholder vote results. Filing
  5. Jun 10, 2026AnnouncementShared information with investors. Filing
  6. May 14, 2026ResultsReleased financial results. Filing
  7. May 8, 2026AgreementImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two… Filing
  8. Apr 14, 2026LeadershipDeparture of Directors; Election of Directors. Filing
  9. Apr 8, 2026ResultsReleased financial results. Filing
  10. Mar 18, 2026LeadershipAs previously disclosed in the Company’s Current Report on Form 8-K filed on February 9, 2026, Steven A. Rosgen gave the Company notice that he preferred not to run for re-election to the Company’s Board of Directors at the 2026 Annual Meeting of Shareholders. Filing
  11. Mar 4, 2026ResultsReleased financial results. Filing
  12. Feb 9, 2026LeadershipDeparture of Directors or Certain Officers, Election of Directors. Filing
  13. Feb 2, 2026LeadershipBelow is hereby incorporated by reference into this Item 1.01. Filing
  14. Jan 8, 2026AnnouncementIn its January 8, 2026 press release (see Exhibit 99.1, incorporated herein by reference), the Company announced that it will host a conference call on Friday, January 9, 2026, at 9:00 AM ET to discuss the unaudited top line results and review its strategic shift to First Defense® and away from… Filing
  15. Dec 29, 2025AnnouncementBelow) that will result in a material charge for a non-cash impairment write-down of certain property, plant and equipment (primarily equipment) during the fourth quarter of 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Immucell financials

Famous investors that hold ICCC

2 of the 50 well-known investors we track reported holding ICCC in their latest 13F filing. The largest position is Jim Simons's, worth $1.7M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026173,389$1.7M0.0%+1%
Ken Griffin · Citadel AdvisorsQ3 202630,177$296K0.0%-25%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Immucell Corp /De/ (ICCC) stock

Who owns the most ICCC stock?

The largest reported owner of Immucell Corp /De/ (ICCC) is Vanguard Capital Management LLC, with 3.0% of the company. In total, 30 funds and institutions reported holding ICCC at the end of Q2 2026, together about 14% of the shares. See the largest owners.

Are ICCC insiders buying or selling?

In the last 12 months, ICCC insiders reported 8 open-market purchases worth $172K and no sales. The latest trade was on Jun 18, 2026. See every trade.

What is the short interest in ICCC?

As of Oct 30, 2026, 14,706 ICCC shares were sold short, 0.2% of the shares outstanding, down 18.8% from the report before. At the average daily volume of 5,271 shares, buying them all back would take about 2.8 trading days (days to cover). See the history.

Which famous investors hold ICCC?

2 of the 50 well-known investors we track reported ICCC in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $1.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.